Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Core Viewpoint - Armata Pharmaceuticals has received $5.25 million in non-dilutive funding from the Department of Defense to support the clinical development of its phage therapy candidate, AP-SA02, for treating complicated Staphylococcus aureus bacteremia [1][2]. Group 1: Funding and Support - The funding is part of a grant managed by the Naval Medical Research Command and aims to advance the clinical development of AP-SA02 [1]. - The grant is intended to help address the urgent need for effective treatments for Staphylococcus aureus bacteremia, which is often resistant to existing antibiotics [2]. Group 2: Clinical Trial Details - The diSArm study is a Phase 1b/2a clinical trial designed to evaluate the safety, tolerability, and efficacy of AP-SA02 as an adjunct to best available antibiotic therapy [2][3]. - Phase 1b focuses on safety and tolerability, while Phase 2a will assess efficacy in subjects with complicated Staphylococcus aureus bacteremia [3]. - The study aims to enroll approximately 50 subjects and is currently 68% enrolled [3]. Group 3: Company Overview - Armata Pharmaceuticals specializes in developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant infections [4]. - The company is advancing a pipeline of phage candidates targeting various pathogens, including Staphylococcus aureus and Pseudomonas aeruginosa [4].